Tag archive for ‘Xyosted launch’
Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy)
Introduction I have heard encouraging comments on my recently announced approach of doing shorter, less pedantic reports on new companies. This is so much so that I am extending this approach to companies that I have actively covered for some time and in this case Antares Pharma. For a Martian with no knowledge of Antares, […]
Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37)
Investment Thesis The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While it is early, I believe that the prescription trends seen over the last six months strongly indicate that the launch will be a success. In this report, I explain the methodology, I used to […]
Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)
Investment Thesis in Brief: In this report, I have put together an earnings forecast projecting EPS of (0.04) in 2019, $0.19 in 2020 and $0.33 in 2021. There are so many variables involved in my forecast that the error bars around these numbers are huge and they should be taken with a grain of salt. […]
Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02
Investment Thesis Antares is one of my top recommendations based on its extremely impressive pipeline prospects. In a March 23, 2017 report Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy) I did an in-depth analysis that goes over my assumptions and resultant projections in great detail for the five partnered products and two […]